TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Cytiva BioProcess R&D AB
Closing information (x1000 DKK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
8,589,112
|
11,367,800
|
10,751,573 |
| Financial expenses |
0
|
7,713
|
9,599 |
| Earnings before taxes |
4,044,656
|
6,616,809
|
5,732,972 |
| EBITDA |
8,237,570
|
11,016,209
|
10,524,964 |
| Total assets |
24,815,882
|
23,662,667
|
19,308,990 |
| Current assets |
10,031,697
|
8,801,979
|
179,418 |
| Current liabilities |
9,564,698
|
15,288,255
|
9,775,869 |
| Equity capital |
15,251,184
|
7,707,407
|
7,755,199 |
| - share capital |
67
|
67
|
73 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
61.5%
|
32.6%
|
40.2% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
47.1%
|
58.2%
|
53.3% |
| Return on assets (ROA) |
16.3%
|
28.0%
|
29.7% |
| Current ratio |
104.9%
|
57.6%
|
1.8% |
| Return on equity (ROE) |
26.5%
|
85.9%
|
73.9% |
| Change turnover |
-2,837,229
|
1,487,111
|
3,510,779 |
| Change turnover % |
-25%
|
15%
|
48% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.